Friday, December 9, 2022
HomeEconomyDilip Shanghvi of Sun Pharmaceutical's to keep stake in Suzlon Energy despite...

Dilip Shanghvi of Sun Pharmaceutical’s to keep stake in Suzlon Energy despite falling value

In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.

Text Size:

New Delhi: Indian billionaire Dilip Shanghvi intends to stay invested in unprofitable wind-turbine maker Suzlon Energy Ltd. even though the company’s financial health has worsened over the last few years.

“If I look at outcome then clearly that investment hasn’t had a great outcome,” Shanghvi said in an interview in Mumbai, adding that Suzlon has to solve its own challenges. Shanghvi, founder and managing director of India’s largest drugmaker Sun Pharmaceutical Industries Ltd., said policy hurdles were responsible for lower demand for Suzlon’s wind turbines and the resultant cash squeeze.

Shanghvi proved a white knight for Suzlon in 2015 when he bought 23 percent stake for 18 billion rupees ($258 million) to help the turbine maker return to profitability after it became India’s largest convertible-bond defaulter in 2012. Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.

Shanghvi said his investment was based on the assessment that within the renewable-energy sector Suzlon had “the product and the future pipeline, which will allow them to grow.”

Over the past two years, India’s shift to auctions for building wind projects from an earlier fixed-tariff program increased competition among suppliers, diluting Suzlon’s market share and putting pressure on its profit margin. The company is losing ground to competitors such as Vestas Wind Systems A/S and Senvion SA, according to Bloomberg NEF.

Ratings assessor Care Ratings Ltd. cut the long-term bank facilities of Suzlon to default from BB in April after it was unable to meet a repayment obligation to its lenders. The company has $172 million in foreign-currency, convertible bonds due in July. .

The company’s market value plunged to 33 billion rupees on Wednesday from a high of 109 billion rupees, a few weeks after Shanghvi announced the investment.

Also read: Monsoon worries are a new headwind for bond rally


Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular